Cellebrite DI (NASDAQ:CLBT) Releases Earnings Results

Cellebrite DI (NASDAQ:CLBT) issued its earnings results on Thursday. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.06, FiscalAI reports. The company had revenue of $131.14 million during the quarter, compared to the consensus estimate of $131.87 million. Cellebrite DI had a return on equity of 18.38% and a net margin of 14.48%.

Here are the key takeaways from Cellebrite DI’s conference call:

• Q2 ARR and revenue fell short of expectations, with ARR rising 21% to $508 million but missing the low end of guidance. Several large government transactions slipped because of new procurement, foreign-entity permitting, and cloud/AI approval requirements.
• Cellebrite reduced its full-year 2026 outlook to $550 million–$560 million of ARR and $555 million–$561 million of revenue, citing slower Inseyets pricing and expansion, elongated deal cycles, and greater caution around large transactions.
• The company raised its full-year adjusted EBITDA outlook to $153 million–$159 million, or a 28% margin, while maintaining confidence in improving free cash flow as headcount remains essentially flat and FX headwinds eventually ease.
• New products are gaining traction: growth products contributed 25% of the sequential ARR increase, Genesis generated about $400,000 of ARR shortly after its launch, and Guardian secured a first major FedRAMP deal with a seven-figure initial order.
• Shiv Ramji became CEO effective immediately in an accelerated succession from Tom Hogan, reflecting the board’s preference for a product-centric leader focused on cloud-native platforms and AI; Cellebrite said the transition has the support of the management team.

Cellebrite DI Trading Up 3.1%

CLBT stock traded up $0.34 during midday trading on Friday, hitting $11.14. 7,843,658 shares of the company’s stock were exchanged, compared to its average volume of 2,143,687. Cellebrite DI has a 12-month low of $9.58 and a 12-month high of $19.98. The firm has a 50 day moving average price of $14.52 and a 200-day moving average price of $14.05. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of 39.79, a price-to-earnings-growth ratio of 1.89 and a beta of 1.18.

Cellebrite DI News Roundup

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Insider Activity

In other news, CFO David Barter sold 41,734 shares of the stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total transaction of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at approximately $5,474,507.22. This represents a 11.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. The trade was a 2.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 297,934 shares of company stock worth $4,631,972. 5.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. raised its stake in shares of Cellebrite DI by 45.1% in the 4th quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock valued at $72,000 after purchasing an additional 1,238 shares in the last quarter. Invesco Ltd. grew its stake in Cellebrite DI by 0.8% in the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock worth $101,026,000 after purchasing an additional 43,041 shares in the last quarter. Corient Private Wealth LLC increased its holdings in Cellebrite DI by 29.8% in the fourth quarter. Corient Private Wealth LLC now owns 107,145 shares of the company’s stock valued at $1,932,000 after buying an additional 24,596 shares during the last quarter. Vident Advisory LLC increased its holdings in Cellebrite DI by 7.1% in the fourth quarter. Vident Advisory LLC now owns 50,887 shares of the company’s stock valued at $917,000 after buying an additional 3,372 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in Cellebrite DI during the fourth quarter valued at approximately $1,300,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Lake Street Capital decreased their price target on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. DA Davidson decreased their target price on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a research note on Friday. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday. Finally, JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.70.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.